Efficacy of a Bioresorbable Matrix in Healing Complex Chronic Wounds: An Open-Label Prospective Pilot Study

被引:0
|
作者
Manning, Sarah W. [1 ]
Humphrey, David A. [1 ]
Shillinglaw, William R. [1 ]
Crawford, Eric [2 ]
Pranami, Gaurav [2 ]
Agarwal, Ankit [2 ]
Schurr, Michael J. [1 ]
机构
[1] Univ North Carolina Hlth Sci, Mt Area Hlth Educ Ctr, Dept Surg, Asheville, NC USA
[2] Imbed Biosci Inc, Madison, WI 53719 USA
基金
美国国家卫生研究院;
关键词
bioresorbable; antimicrobial; silver; matrix; chronic; wound; infection; SILVER DRESSINGS; CYTOTOXICITY; MANAGEMENT; SYMPTOMS; TISSUE; CELL;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective. The goal of this prospective clinical study was to assess the effectiveness of a novel bioresorbable polymeric matrix impregnated with ionic and metallic silver as a primary wound contact dressing in healing stagnant or deteriorating chronic wounds. Materials and Methods. Thirty-two patients with a total of 35 chronic wounds undergoing treatment at the Wound Healing and Hyperbaric Center at Mission Hospital were recruited under a protocol approved by the institutional review board. The wounds included venous stasis ulcers, diabetic foot ulcers, postoperative surgical wounds, burn wounds, and chronic, nonpressure lower extremity ulcers. At baseline, all wounds were nonhealing (ie, stagnant or deteriorating) for a median of 39 weeks (range, 3-137 weeks) and suspected of persistent microbial colonization that had not responded to traditional antimicrobial products and/or antibiotics. The aforementioned matrix was applied to wounds once every 3 days and covered with a secondary dressing. Previously prescribed protocols of care, such as debridement or compression wraps, were continued, but prior antimicrobial dressings or antibiotics were replaced with the matrix. Wound assessments at 3 weeks and 12 weeks post intervention are reported. Results. Three patients were excluded due to patients lost to follow-up after initial application. At 3 weeks, 72% of wounds (22/32) had significantly improved healing with an average wound area reduction of 66%. By 12 weeks, 91% of wounds (29/32) either healed completely (ie, fully reepithelialized) or improved significantly with an average wound area reduction of 73%. The matrix was well tolerated; no patient reported discomfort with the application of the matrix. Conclusions. The micrometer-thick bioresorbable matrix presents a new form factor to wound management, conforming intimately to the underlying wound bed to exert localized and sustained antimicrobial action of noncytotoxic levels of silver. The application of the matrix on the wound surface in protocols of care was safe and well tolerated, and it facilitated improvements in healing of a majority of the stagnant or deteriorating complex chronic wounds.
引用
收藏
页码:309 / 318
页数:10
相关论文
共 50 条
  • [1] Effectiveness of Oral Tofacitinib in Chronic Pouchitis: A Prospective, Open-Label Pilot Study
    Syal, Gaurav
    Mishkin, Daniel S.
    Banty, Andrea
    Lee, Susie
    Fontelera, Norma
    Hampton, Melissa
    Ziring, David
    Fleshner, Phillip R.
    Melmed, Gil Y.
    INFLAMMATORY BOWEL DISEASES, 2023,
  • [2] A prospective, open-label study to assess the clinical performance of a foam dressing in the management of chronic wounds
    Zoellner, Petra
    Kapp, Holger
    Smola, Hans
    OSTOMY WOUND MANAGEMENT, 2006, 52 (05) : 34 - +
  • [3] Prospective, Single-center, Open-label, Pilot Study Using Cryopreserved Umbilical Tissue Containing Viable Cells in the Treatment of Complex Acute and Chronic Wounds
    Mullins, Robert F.
    Hassan, Zaheed
    Homsombath, Bounthavy
    Fagan, Shawn
    Craft-Coffman, Beretta
    Wilson, Joan
    Rumbaugh, John G.
    Saunders, Molly
    Danilkovitch, Alla
    WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE, 2020, 32 (08): : 221 - 227
  • [4] An Open-Label, Prospective, Pilot Study of Hypertonic Saline for Hidradenitis Suppurativa
    Porter, Martina L.
    Salian, Prerna
    Rosales Santillan, Monica
    Greif, Charlotte
    Kimball, Alexa B.
    DERMATOLOGIC SURGERY, 2022, 48 (09) : 954 - 960
  • [5] Zonisamide in the Treatment of Bulimia Nervosa: An Open-Label, Pilot, Prospective Study
    Guerdjikova, Anna I.
    Blom, Thomas J.
    Martens, Brian E.
    Keck, Paul E., Jr.
    McElroy, Susan L.
    INTERNATIONAL JOURNAL OF EATING DISORDERS, 2013, 46 (07) : 747 - 750
  • [6] Efficacy and Safety of IncobotulinumtoxinA for the Treatment of Platysmal Bands of the Aging Neck: An Open-Label, Prospective Pilot Study
    Gubanova, Elena I.
    Panova, Olga S.
    Sanchez, Elena A.
    Rodina, Maria Y.
    Starovatova, Polina A.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2013, 12 (12) : 1461 - 1466
  • [7] An open-label pilot study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine
    Virgilio Gallai
    Andrea Alberti
    Cristiana Rossi
    Francesca Coppola
    Beatrice Gallai
    Giovanni Mazzotta
    Paola Sarchielli
    The Journal of Headache and Pain, 2003, 4 (2) : 92 - 96
  • [8] Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial
    Fukushima, Yasushi
    Suzuki, Hidekazu
    Matsuzaki, Juntaro
    Kiyosue, Arihiro
    Hibi, Toshifumi
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2012, 18 (03) : 317 - 323
  • [9] Treatment of chronic alopecia areata with tildrakizumab: an open-label pilot study
    Kerkemeyer, Karolina L. S.
    Sinclair, Rodney
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2020, 59 (05) : E136 - E137
  • [10] Efficacy and safety of ustekinumab for chronic antibiotic refractory pouchitis: A Belgian open-label multicentre pilot study
    Outtier, A.
    Louis, E.
    Dewit, O.
    Schops, G.
    Verstockt, B.
    Sabino, J.
    Vermeire, S.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I460 - I461